- Home
- TLSI vs PRQR Comparison
TLSI vs PRQR Comparison
Compare TLSI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- PRQR
- Stock Information
- Founded
- TLSI 2010
- PRQR 2012
- Country
- TLSI United States
- PRQR Netherlands
- Employees
- TLSI N/A
- PRQR N/A
- Industry
- TLSI Medical Specialities
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- PRQR Health Care
- Exchange
- TLSI Nasdaq
- PRQR Nasdaq
- Market Cap
- TLSI 204.0M
- PRQR 179.1M
- IPO Year
- TLSI N/A
- PRQR 2014
- Fundamental
- Price
- TLSI $5.43
- PRQR $2.04
- Analyst Decision
- TLSI Strong Buy
- PRQR Strong Buy
- Analyst Count
- TLSI 5
- PRQR 8
- Target Price
- TLSI $10.90
- PRQR $8.88
- AVG Volume (30 Days)
- TLSI 146.8K
- PRQR 355.0K
- Earning Date
- TLSI 08-13-2025
- PRQR 08-07-2025
- Dividend Yield
- TLSI N/A
- PRQR N/A
- EPS Growth
- TLSI N/A
- PRQR N/A
- EPS
- TLSI N/A
- PRQR N/A
- Revenue
- TLSI $32,141,000.00
- PRQR $21,212,711.00
- Revenue This Year
- TLSI $55.52
- PRQR N/A
- Revenue Next Year
- TLSI $54.76
- PRQR N/A
- P/E Ratio
- TLSI N/A
- PRQR N/A
- Revenue Growth
- TLSI 46.20
- PRQR 85.91
- 52 Week Low
- TLSI $3.50
- PRQR $1.07
- 52 Week High
- TLSI $6.04
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- TLSI 50.01
- PRQR 71.54
- Support Level
- TLSI $5.18
- PRQR $1.89
- Resistance Level
- TLSI $5.65
- PRQR $2.20
- Average True Range (ATR)
- TLSI 0.35
- PRQR 0.11
- MACD
- TLSI -0.02
- PRQR 0.02
- Stochastic Oscillator
- TLSI 49.23
- PRQR 90.70
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.